公开(公告)号：EP4265724A1

公开(公告)日：2023-10-25

申请号：EP21907187.5

申请日：2021-12-20

申请人： OliX Pharmaceuticals, Inc.

发明人： HONG, Sun Woo ,  DUA, Pooja

IPC分类号： C12N15/113 ,  A61K31/7088 ,  A61K48/00 ,  A61P31/20

摘要： The present application relates to an RNA interference (RNAi) agent for inhibiting the expression of hepatitis B virus and uses thereof, and to an RNAi agent that inhibits the expression of hepatitis B virus and a pharmaceutical composition including the RNAi agent for amelioration or treatment of diseases caused by hepatitis B virus infection.

公开(公告)号：EP3974531A1

公开(公告)日：2022-03-30

申请号：EP20809923.4

申请日：2020-05-20

申请人： Olix Pharmaceuticals, Inc.

发明人： LEE, Dong Ki ,  KANG, Younggue ,  DUA, Pooja

IPC分类号： C12N15/113 ,  C12N5/0783 ,  A61K31/7088 ,  A61K35/17 ,  A61P35/00

摘要： The present invention relates to an asymmetric siRNA that may inhibit expression of programmed cell death protein 1 (PD-1), and a use thereof, and more specifically, to: an asymmetric siRNA including an antisense strand including a sequence complementary to mRNA encoding PD-1, and a sense strand forming complementary bonds with the antisense strand; a pharmaceutical composition for preventing or treating cancer, including the asymmetric siRNA; an immune cell in which expression of PD-1 is inhibited, obtained by treatment with the siRNA; and an immune cell therapeutic agent for treating cancer, including the immune cell.